JP2020537690A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020537690A5 JP2020537690A5 JP2020542037A JP2020542037A JP2020537690A5 JP 2020537690 A5 JP2020537690 A5 JP 2020537690A5 JP 2020542037 A JP2020542037 A JP 2020542037A JP 2020542037 A JP2020542037 A JP 2020542037A JP 2020537690 A5 JP2020537690 A5 JP 2020537690A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- seq
- antigen
- binding fragment
- chain variable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023127717A JP2023155262A (ja) | 2017-10-11 | 2023-08-04 | プレクチン１結合抗体およびその使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762571246P | 2017-10-11 | 2017-10-11 | |
| US62/571,246 | 2017-10-11 | ||
| PCT/US2018/055438 WO2019075216A1 (en) | 2017-10-11 | 2018-10-11 | ANTIBODIES BINDING TO PELTIN-1 AND USES THEREOF |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023127717A Division JP2023155262A (ja) | 2017-10-11 | 2023-08-04 | プレクチン１結合抗体およびその使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020537690A JP2020537690A (ja) | 2020-12-24 |
| JP2020537690A5 true JP2020537690A5 (https=) | 2022-03-18 |
| JP7379347B2 JP7379347B2 (ja) | 2023-11-14 |
Family
ID=66101714
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020542037A Active JP7379347B2 (ja) | 2017-10-11 | 2018-10-11 | プレクチン１結合抗体およびその使用 |
| JP2023127717A Pending JP2023155262A (ja) | 2017-10-11 | 2023-08-04 | プレクチン１結合抗体およびその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023127717A Pending JP2023155262A (ja) | 2017-10-11 | 2023-08-04 | プレクチン１結合抗体およびその使用 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US12053530B2 (https=) |
| JP (2) | JP7379347B2 (https=) |
| CN (1) | CN112105380A (https=) |
| WO (1) | WO2019075216A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102486507B1 (ko) | 2016-04-08 | 2023-01-09 | 아이티아이 헬스, 인크. | 플렉틴-1 결합 항체 및 그의 용도 |
| JP7379347B2 (ja) * | 2017-10-11 | 2023-11-14 | ジィールバイオ，インコーポレーテッド | プレクチン１結合抗体およびその使用 |
| GB202012761D0 (en) * | 2020-08-14 | 2020-09-30 | Univ Oxford Brookes | Metastatis treatment or prevention |
| US20250011418A1 (en) * | 2021-10-29 | 2025-01-09 | Zielbio, Inc. | Cancer specific plectin-1 specific antibodies and methods of use thereof |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| EP0281604B1 (en) | 1986-09-02 | 1993-03-31 | Enzon Labs Inc. | Single polypeptide chain binding molecules |
| US5260203A (en) | 1986-09-02 | 1993-11-09 | Enzon, Inc. | Single polypeptide chain binding molecules |
| US7829084B2 (en) * | 2001-01-17 | 2010-11-09 | Trubion Pharmaceuticals, Inc. | Binding constructs and methods for use thereof |
| US7754208B2 (en) | 2001-01-17 | 2010-07-13 | Trubion Pharmaceuticals, Inc. | Binding domain-immunoglobulin fusion proteins |
| US20040101874A1 (en) * | 2002-04-12 | 2004-05-27 | Mitokor Inc. | Targets for therapeutic intervention identified in the mitochondrial proteome |
| US20050164324A1 (en) | 2003-06-04 | 2005-07-28 | Gygi Steven P. | Systems, methods and kits for characterizing phosphoproteomes |
| US7842466B1 (en) | 2005-09-16 | 2010-11-30 | Celera Corporation | Colon disease targets and uses thereof |
| US20090110680A1 (en) * | 2006-04-07 | 2009-04-30 | Stephanie Sieger | Combination of an anti ED-B fibronectin domain antibody and gemcitabine |
| JP2011501731A (ja) | 2007-09-10 | 2011-01-13 | ユニバーシティ オブ マサチューセッツ | ミトコンドリア標的化抗腫瘍剤 |
| WO2009079585A2 (en) | 2007-12-17 | 2009-06-25 | Dyax Corp. | Compositions and methods for treating osteolytic disorders comprising mmp-14 binding proteins |
| JP5497006B2 (ja) | 2008-04-14 | 2014-05-21 | ザ ジェネラル ホスピタル コーポレイション | 膵管腺癌の検出および治療のためのプレクチン−１標的化剤 |
| WO2011057078A2 (en) | 2009-11-05 | 2011-05-12 | University Of Virginia Patent Foundation | Compositions and methods for detecting plectin-1 as a biomarker for cancer |
| WO2014028668A2 (en) * | 2012-08-14 | 2014-02-20 | Minerva Biotechnologies Corporation | Stem cell enhancing therapeutics |
| US9856315B2 (en) | 2014-10-15 | 2018-01-02 | Cell Signaling Technology, Inc. | Methylation and acetylation sites |
| US10611796B2 (en) | 2016-03-16 | 2020-04-07 | Council Of Scientific & Industrial Research | Method for regressing pancreatic tumor by a liposomal formulation along with DNA vaccines |
| KR102486507B1 (ko) * | 2016-04-08 | 2023-01-09 | 아이티아이 헬스, 인크. | 플렉틴-1 결합 항체 및 그의 용도 |
| JP7379347B2 (ja) * | 2017-10-11 | 2023-11-14 | ジィールバイオ，インコーポレーテッド | プレクチン１結合抗体およびその使用 |
-
2018
- 2018-10-11 JP JP2020542037A patent/JP7379347B2/ja active Active
- 2018-10-11 WO PCT/US2018/055438 patent/WO2019075216A1/en not_active Ceased
- 2018-10-11 CN CN201880079957.6A patent/CN112105380A/zh active Pending
-
2020
- 2020-04-10 US US16/846,031 patent/US12053530B2/en active Active
-
2023
- 2023-08-04 JP JP2023127717A patent/JP2023155262A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Emami et al. | Doxorubicin and anti-PD-L1 antibody conjugated gold nanoparticles for colorectal cancer photochemotherapy | |
| Gibson | Platinum (IV) anticancer agents; are we en route to the holy grail or to a dead end? | |
| Zhang et al. | Near-infrared light irradiation induced mild hyperthermia enhances glutathione depletion and DNA interstrand cross-link formation for efficient chemotherapy | |
| Fraguas-Sánchez et al. | Current status of nanomedicine in the chemotherapy of breast cancer | |
| Svenson | Clinical translation of nanomedicines | |
| Jung et al. | Cell nucleus-targeting zwitterionic carbon dots | |
| JP2020537690A5 (https=) | ||
| Meng et al. | Intracellular drug release nanosystems | |
| Clementi et al. | Dendritic poly (ethylene glycol) bearing paclitaxel and alendronate for targeting bone neoplasms | |
| JP2023155262A5 (https=) | ||
| Houdaihed et al. | Dual-Targeted Delivery of Nanoparticles Encapsulating Paclitaxel and Everolimus: a Novel Strategy to Overcome Breast Cancer Receptor Heterogeneity: Houdaihed, Evans and Allen | |
| EP3346997A1 (en) | Bioorthogonal compositions | |
| Emoto et al. | Antitumor effect and pharmacokinetics of intraperitoneal NK 105, a nanomicellar paclitaxel formulation for peritoneal dissemination | |
| Du et al. | Combined phycocyanin and hematoporphyrin monomethyl ether for breast cancer treatment via photosensitizers modified Fe3O4 nanoparticles inhibiting the proliferation and migration of MCF-7 cells | |
| Molavi et al. | Anti-CD30 antibody conjugated liposomal doxorubicin with significantly improved therapeutic efficacy against anaplastic large cell lymphoma | |
| Fu et al. | Chemo-immune synergetic therapy of esophageal carcinoma: trastuzumab modified, cisplatin and fluorouracil co-delivered lipid–polymer hybrid nanoparticles | |
| Zhao et al. | Research progress of conjugated nanomedicine for cancer treatment | |
| Sahli et al. | Temozolomide, gemcitabine, and decitabine hybrid nanoconjugates: from design to proof-of-concept (PoC) of synergies toward the understanding of drug impact on human glioblastoma cells | |
| Bai et al. | Photodynamic gel-bombs enhance tumor penetration and downstream synergistic therapies | |
| Li et al. | Cisplatin-based combination therapy for enhanced cancer treatment | |
| Babu Varukattu et al. | Targeted and intrinsic activity of HA-functionalized PEI-nanoceria as a nano reactor in potential triple-negative breast cancer treatment | |
| Xiao et al. | Use of anticancer platinum compounds in combination therapies and challenges in drug delivery | |
| Lan et al. | CD44-targeted photoactivatable polymeric nanosystem with on-demand drug release as a “photoactivatable bomb” for combined photodynamic therapy–chemotherapy of cancer | |
| Sun et al. | Substance P mediated DGLs complexing with DACHPt for targeting therapy of glioma | |
| Hunt | Precision targeting of intraperitoneal tumors with peptideguided nanocarriers |